V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

AbCellera Biologics Executive Compensation (FY25)

ABCL · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Carl Hansen
Latest say-on-pay support
=
June 11, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.

The AbCellera Biologics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 18, 2026Latest filing (8-K): June 12, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
AbCellera Biologics brief$1,500Get the executive brief
Velarion Member, one year
197 figures on this page: 192 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Carl Hansen: $8,245,492 → $6,293,085 (23.7% lower)
Say-on-pay support: 88.9% → 92.9% (4.0 points higher)
CEO pay ratio: 63:1 → 52:1 (17.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is AbCellera Biologics' chief executive and what were they paid?
Carl Hansen was paid $6,293,085 in total compensation as Chief Executive Officer for fiscal 2025. Hansen's total was 23.7% lower than the $8,245,492 reported for fiscal 2024.
What was AbCellera Biologics' say-on-pay result?
The say-on-pay proposal drew 92.9% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in AbCellera Biologics' peer group?
The disclosed peer group includes Absci, Adaptive Biotechnologies, Agios Pharmaceuticals, Allogene Therapeutics and Arcutis Biotherapeutics, among others.
What is AbCellera Biologics' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 52:1, against median employee compensation of $122,119.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Carl Hansen
Chief Executive Officer
◇◇—◇——◇◇
Neil Aubuchon
Chief Commercial Officer
◇◇◇◇◇—◇— not reconciled
Andrew Booth
Chief Financial Officer
◇◇—◇——◇◇
Véronique Lecault
Chief Operating Officer
◇◇—◇——◇◇
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
◇◇—◇——◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Carl Hansen
Chief Executive Officer
◇◇————◇◇
Andrew Booth
Chief Financial Officer
◇◇————◇◇
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer
◇◇————◇◇
Véronique Lecault
Chief Technology Officer
◇◇————◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Carl Hansen
Chief Executive Officer
◇◇—◇——◇◇
Andrew Booth
Chief Financial Officer
◇◇—◇——◇◇
Véronique Lecault
Chief Technology Officer
◇◇—◇——◇◇
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer
◇◇—◇——◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Carl Hansen
Chief Executive Officer
◇◇—◇——◇◇
Andrew Booth
Chief Financial Officer
◇◇—◇——◇◇
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer
◇◇—◇——◇◇
Véronique Lecault
Chief Technology Officer
◇◇—◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew BoothOPTION◇——◇—◇◇
Carl L.G. HansenOPTION◇——◇—◇◇
Tryn StimartOPTION◇——◇—◇◇
Véronique LecaultOPTION◇——◇—◇◇
Fiscal 2022, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Véronique LecaultOption◇—◇1/14/2034
Option◇—◇1/1/2035
Option◇—◇12/1/2032
Carl HansenOption◇—◇1/1/2035
Option◇—◇1/14/2034
Option◇—◇12/1/2032
Andrew BoothOption◇—◇1/1/2035
Option◇—◇1/14/2034
Option◇—◇12/1/2032
Tryn StimartOption◇—◇1/1/2035
Option◇—◇1/14/2034
Option◇—◇12/1/2032
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Andrew Booth
Chief Financial Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Carl Hansen
Chief Executive Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Tryn Stimart
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary, and Privacy Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇
Véronique Lecault
Chief Technology Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-compete period◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Hayden
◇—◇———◇
John S. Montalbano
◇—◇———◇
Andrew Lo
◇—◇———◇
Stephen R. Quake
◇—◇———◇
Carl L.G. Hansen and Véronique Lecault served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Absci ABSI
  • Adaptive Biotechnologies ADPT
  • Agios Pharmaceuticals AGIO
  • Allogene Therapeutics ALLO
  • Arcutis Biotherapeutics ARQT
  • Entrada Therapeutics TRDA
  • Ligand Pharmaceuticals LGND
  • Nurix Therapeutics NRIX
  • Prime Medicine PRME
  • Recursion Pharmaceuticals RXRX
  • Regenxbio RGNX
  • Relay Therapeutics RLAY
  • Sana Biotechnology SANA
  • Spyre Therapeutics SYRE
  • Structure Therapeutics GPCR
  • Verve Therapeutics VERV
  • Vir Biotechnology VIR
  • Xencor XNCR
  • Xenon Pharmaceuticals XENE
  • Y-mAbs Therapeutics YMAB

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2024June 12, 2025=◇◇◇
2023June 13, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 15, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when AbCellera Biologics files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact AbCellera Biologics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where AbCellera Biologics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether AbCellera Biologics' disclosed peer group is defensible, who names AbCellera Biologics back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
197 figures on this page: 192 cited to the filing that reported them, 5 calculated from figures it prints.
192 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001703057-26-000033
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001703057-26-000020
    Compensation Discussion and Analysis · DIRECTOR COMPENSATION
  3. 0001628280-25-031219
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001628280-25-020703
  5. 0001628280-24-028097
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001628280-24-019019
    2023 Summary Compensation Table
  7. 0001703057-23-000014
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001140361-23-021664
    2022 Summary Compensation Table
  9. 0001564590-22-023707
    Say-on-Pay Proposal
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “AbCellera Biologics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ABCL (accessed 2026).
Short form: data: Velarion

The AbCellera Biologics brief, $1,500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about AbCellera Biologics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers AbCellera Biologics discloses

The companies named in ABCL's own disclosed peer group.

AbsciAdaptive BiotechnologiesAgios PharmaceuticalsAllogene TherapeuticsArcutis BiotherapeuticsEntrada TherapeuticsLigand PharmaceuticalsNurix TherapeuticsPrime MedicineRecursion PharmaceuticalsRegenxbioRelay TherapeuticsSana BiotechnologySpyre TherapeuticsStructure TherapeuticsVerve TherapeuticsVir BiotechnologyXencorXenon PharmaceuticalsY-mAbs Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy